Chidamide after stem cell transplant for AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a drug called chidamide (Cidabenamide) as maintenance therapy after a stem cell transplant for people with intermediate or high-risk AML. The goal is to see if it helps prevent the leukemia from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You had intermediate or high-risk AML and your leukemia went into complete remission after your stem cell transplant.
- You are between 60 and 100 days past your transplant.
- You do not have a FLT3 mutation in your leukemia cells.
- You do not have uncontrolled graft-versus-host disease (GVHD) or an active infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs (chidamide, venetoclax, azacitidine, and homoharringtonine) for people newly diagnosed with high-risk acute myeloid leukemia (AML) who are otherwise healthy enough to receive intensive treatment. The goal is to see if this combination is safe and effective.
This trial tests a new drug for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard therapies, and whose leukemia has certain genetic markers. The drug may target these specific changes to help stop the cancer.
This Phase 1/2 study tests whether chidamide can help prevent high-risk acute myeloid leukemia (AML) from coming back after an allogeneic bone marrow transplant (allo-HSCT). Participants must already be in complete remission and have recovered blood counts after transplant.
This study tests a maintenance drug called chidamide, which may help keep your T-cell leukemia or lymphoma from returning after a stem cell transplant. You will take this drug as a pill to see if it extends the time you stay cancer-free.
This trial tests two medicines given after a bone-marrow transplant to help lower the chance of acute myeloid leukemia (AML) coming back. It is aimed at people with higher-risk AML and checks safety along with whether the medicines can help prevent relapse.
This trial tests whether a combination of two drugs, chidamide and azacitidine (AZA), can help people with acute myeloid leukemia (AML) who still have small amounts of leukemia cells (called MRD) after a stem cell transplant. The goal is to see if this treatment can clear those leftover cells and lower the chance of the leukemia coming back.
Hear when a new Allogeneic Hematopoietic Cell Transplantation (HCT) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.